Brainstorm Cell Therapeutics (Brainstorm Cell Therapeutics) Debt-to-Equity : -0.26 (As of Dec. 2023)

View and export this data going back to 2003. Start your Free Trial

What is Brainstorm Cell Therapeutics Debt-to-Equity?

Brainstorm Cell Therapeutics's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $0.60 Mil. Brainstorm Cell Therapeutics's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $0.67 Mil. Brainstorm Cell Therapeutics's Total Stockholders Equity for the quarter that ended in Dec. 2023 was $-4.86 Mil. Brainstorm Cell Therapeutics's debt to equity for the quarter that ended in Dec. 2023 was -0.26.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for Brainstorm Cell Therapeutics's Debt-to-Equity or its related term are showing as below:

BCLI' s Debt-to-Equity Range Over the Past 10 Years
Min: -1.36 Med: -0.19 Max: 0.26
Current: -0.26

During the past 13 years, the highest Debt-to-Equity Ratio of Brainstorm Cell Therapeutics was 0.26. The lowest was -1.36. And the median was -0.19.

BCLI's Debt-to-Equity is not ranked
in the Biotechnology industry.
Industry Median: 0.15 vs BCLI: -0.26

Brainstorm Cell Therapeutics Debt-to-Equity Historical Data

The historical data trend for Brainstorm Cell Therapeutics's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Brainstorm Cell Therapeutics Debt-to-Equity Chart

Brainstorm Cell Therapeutics Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Debt-to-Equity

Get a 7-Day Free Trial

-0.19

0.20

0.26

-1.36

-0.26

Brainstorm Cell Therapeutics Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Debt-to-Equity	Get a 7-Day Free Trial															-1.36	-0.76	-0.85	-1.12	-0.26

Competitive Comparison of Brainstorm Cell Therapeutics's Debt-to-Equity

For the Biotechnology subindustry, Brainstorm Cell Therapeutics's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Brainstorm Cell Therapeutics's Debt-to-Equity Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Brainstorm Cell Therapeutics's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where Brainstorm Cell Therapeutics's Debt-to-Equity falls into.

Brainstorm Cell Therapeutics Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

Brainstorm Cell Therapeutics's Debt to Equity Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(0.603	+	0.672)	/	-4.858
	=	-0.26

Brainstorm Cell Therapeutics's Debt to Equity Ratio for the quarter that ended in Dec. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(0.603	+	0.672)	/	-4.858
	=	-0.26

Brainstorm Cell Therapeutics (NAS:BCLI) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

Brainstorm Cell Therapeutics Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of Brainstorm Cell Therapeutics's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Brainstorm Cell Therapeutics (Brainstorm Cell Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Brainstorm Cell Therapeutics Inc (NAS:BCLI) » Definitions » Debt-to-Equity

Comparable Companies

Traded in Other Exchanges

GHDN:Germany GHDN:Germany

Address

1325 Avenue of Americas, 28th Floor, New York, NY, USA, 10019

Website

https://www.brainstorm-cell.com

Brainstorm Cell Therapeutics Inc is a biotechnology company. The company is developing novel adult stem cell therapies for debilitating neurodegenerative disorders such as Amyotrophic Lateral Sclerosis (ALS, also known as Lou Gehrig's disease), Progressive Multiple Sclerosis (PMS), and Parkinson's disease (PD). Brainstorm's NurOwn, its proprietary process for the propagation of Mesenchymal Stem Cells (MSC) and differentiation into neurotrophic factor-(NTF) secreting cells (MSC-NTF), and their transplantation at, or near, the site of damage, offers the hope of more effectively treating neurodegenerative diseases.

Executives

Stacy Lindborg	officer: EVP, Head Global Clin Research	C/O BRAINSTORM CELL THERAPEUTICS, INC., 1325 AVENUE OF AMERICAS, 28TH FLR., NEW YORK NY 10019
Nir Naor	director	BRAINSTORM CELL THERAPEUTICS, INC., 1325 AVENUE OF AMERICAS, 28TH FLOOR, NEW YORK NY 10019
Kirk Taylor	officer: Chief Medical Officer	C/O BRAINSTORM CELL THERAPEUTICS INC., 1325 AVENUE OF AMERICAS, 28TH FLOOR, NEW YORK NY 10019
Menghisteab Bairu	director	C/O BRAINSTORM CELL THERAPEUTICS INC., 1325 AVENUE OF THE AMERICAS 28TH FL, NEW YORK NY 10019
Alla Patlis	officer: See Remarks	C/O BRAINSTORM CELL THERAPEUTICS, INC., 3 UNIVERSITY PLAZA DRIVE, SUITE 320, HACKENSACK NJ 07601
Anthony Waclawski	officer: See Remarks	C/O BRAINSTORM CELL THERAPEUTICS, INC., 1325 AVENUE OF THE AMERICAS 28TH FL, NEW YORK NY 10019
Chaim Lebovits	officer: Chief Executive Officer	110 EAST 59TH STREET, NEW YORK NY 10019
David Setboun	officer: EVP and COO	C/O BRAINSTORM CELL THERAPEUTICS, INC., 1325 AVENUE OF AMERICAS, 28TH FLOOR, NEW YORK NY 10019
Acc International Holdings Ltd.	other: Member of 10% owner group	MORGAN & MORGAN BUILDING, PASEA ESTATE, ROAD TOWN, TORTOLA D8 VG 1110
Sankesh Abbhi	director	3119 PONCE DE LEON, UNIT C, CORAL GABLES FL 33134
Jacob A Frenkel	director	188 E. 70TH ST., #29A, NEW YORK NY 10021
Arturo Araya	officer: Chief Commercial Officer	C/O BRAINSTORM CELL THERAPEUTICS, INC., 3 UNIVERSITY PLAZA DRIVE, SUITE 320, HACKENSACK NJ 07601
Preetam Shah	officer: EVP, CFO and Treasurer	C/O BRAINSTORM CELL THERAPEUTICS, INC., 1325 AVENUE OF AMERICAS, 28TH FLR., NEW YORK NY 10019
Ralph Dr. Kern	officer: COO and Chief Medical Officer	C/O BRAINSTORM CELL THERAPEUTICS, INC., 3 UNIVERSITY PLAZA DRIVE, SUITE 320, HACKENSACK NJ 07601
Irit Arbel	director	6 HADISHON STREEET, JERUSALEM, ISRAEL 96596 L3 00000